Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial contact site and cristae organizing system subunit 13 (MICOS13), also known as MIC13, QIL1, or C19orf70, is a small (9.7 kDa, 88 amino acids) protein located in the inner membrane of mitochondria[2][3]. MICOS13 is a crucial component of the MICOS complex, which is responsible for maintaining the integrity and shape of mitochondrial cristae junctions, structures essential for mitochondrial respiration and function[1][3][7]. It facilitates the incorporation of other MICOS subunits and is necessary for the proper formation of cristae junctions and mitochondrial architecture[2][3][7]. Mutations in MICOS13 lead to disruption of mitochondrial structure and severe mitochondrial diseases, including combined oxidative phosphorylation deficiency and mitochondrial DNA depletion syndrome, especially hepatocerebral forms with early-onset encephalopathy and liver dysfunction[4]. MICOS13 is not a classic pharmacological target (e.g., enzyme, receptor), but rather a mitochondrial structural protein critical for organelle integrity and bioenergetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial contact site and cristae organizing system subunit 13 (MICOS13).